A Sofinnova-backed CAR-T maker has shut down its New York and Princeton, NJ sites and will continue operating out of its Paris hub.

Mnemo Therapeutics turned the lights off at its US operations effective immediately on Feb. 23, according to employees’ posts on LinkedIn and confirmation from co-founder and operating chief Alain Maiore.

“When Sebastian [Amigorena] and I started Mnemo Tx, we were looking to build a company where the human value of ‘standing shoulder to shoulder’ in difficult time would typify the DNA of our teams across the ocean,” Maiore wrote on LinkedIn in recent days. “The decision we had to make about shutting down our US operations, to move back our CT effort to Europe, next to our target discovery platform was a very difficult one.”

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

SIGN UP LOG IN

These days, when Jeffrey Bluestone gets together with his contemporaries in science, the conversation often turns to retirement plans.

But a little more than three years ago, Bluestone reached a momentous turning point in his career, exiting a prestigious post at UCSF, where he had spent decades in the scientific pursuit of new therapies. And it had nothing to do with retirement anytime in the near future.

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

SIGN UP LOG IN

In 2015, now-FDA Commissioner Robert Califf joined industry, academic and regulatory representatives in Washington to discuss why more drugs weren’t in development for cardiovascular diseases, the leading US cause of death and once a mainstay of pharmaceutical industry blockbusters.

The group pointed to many reasons. Clinical trials could take years and testing was expensive. Wide availability of generic drugs made the commercial prospects uncertain. Their paper title summed up the mood: “Cardiovascular Drug Development: Is it Dead or Just Hibernating?”

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

SIGN UP LOG IN

From the political arena to the finance and beauty industries to pharmaceuticals, Pfizer’s Sally Susman has broken barriers, stereotypes and conventions. And now the chief communicator is “Breaking Through,” the title of her first book about effective and innovative communications launching today. The full official title is “Breaking Through: Communicating to Open Minds, Move Hearts, and Change the World.”

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

SIGN UP LOG IN